血脂康胶囊对冠心病患者血管内皮功能及氧化还原态的影响

Effects of Xuezhikang Capsules on vascular endothelial function and redox status in patients with coronary heart disease

目的:探讨血脂康胶囊和普罗布考对冠心病患者的降脂作用及其对血管内皮功能、氧化还原态的影响。方法:112例冠心病患者,随机分为血脂康组(56例)和普罗布考组(56例)。治疗前及治疗8周后,检测2组患者血总胆固醇(total cholesterol,TC)、甘油三酯(triglycerides,TG)、低密度脂蛋白胆固醇(lowdensity lipoprotein cholesterol,LDL-C)、一氧化氮(nitric oxide,NO)、内皮-素1(endothelin-1,ET-1)、还原型谷胱甘肽(glutathione,GSH)和氧化型谷胱甘肽(oxidized glutathione,GSSG)的水平,并计算GSH/GSSG氧化还原电位。结果:血脂康组患者治疗后血TC、LDL-C和TG水平较治疗前降低,普罗布考组患者血TC、LDL-C水平较治疗前降低,差异均有统计学意义。血脂康组患者治疗后血ET-1、GSSG水平及GSH/GSSG氧化还原电位较治疗前降低,血GSH、NO水平及NO/ET-1、GSH/GSSG比值较治疗前升高,差异均有统计学意义。结论:血脂康胶囊和普罗布考对冠心病患者均有降脂作用。血脂康胶囊对血管内皮功能具有一定的保护作用,可使GSH/GSSG氧化还原态向还原方向偏移。

Objective. To explore the effects of Xuezhikang Capsules （ZXKC） and probucol on blood lipids, vascular endothelial functions and redox status in patients with coronary heart disease. Methods. One hundred and twelve patients with coronary heart disease were randomly divided into XZKC-treated group and probucol-treated group, 56 in each. Before and after 8-week treatment, the blood levels of total cholesterol （TO）, triglycerides （TG）, low density lipoprotein cholesterol （LDL-C）, nitric oxide （NO）, endothelin-1 （ET- 1）, reduced glutathione （GSH） and oxidized glutathione （GSSG） were all measured in both groups. The GSH/GSSG redox potential （Eh） was calculated according to the Nernst equation, Results： In the XZKC-treated group, the blood levels of TC, LDL-C and TG were significantly decreased after 8-week treatment as compared with those before treatment, The blood levels of TO and LDL-C were also significantly decreased in the probucol-treated group as compared with those before treatment, In the XZKC-treated group, the blood levels of ET-1 and GSSG and the GSH/GSSG Eh after treatment were all significantly lower than those before treatment, whereas the blood levels of GSH and NO, the NO/ET-1 ratio, and the GSH/GSSG ratio after treatment were all significantly higher than those before treatment. Conclusion： The X7KC or probucol treatment can yield a significant decrease in blood lipids in patients with coronary heart disease. Furthermore, XZKC exerts effective protection on vascular endothelial function, and can make GSH/GSSG redox status shift towards deoxidation.